A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Harmony Biosciences Holdings, Inc.
HRMY
$2.1B
Mkt Cap
$35.32
-1.34%
Harmony Biosciences Holdings, Inc. (HRMY) has a current P/E ratio of 13.0, compared to its historical median P/E of 15.6. The stock is currently considered Fair based on its historical valuation range.
Harmony Biosciences Holdings, Inc. (HRMY) has a 5-year average return on invested capital (ROIC) of 54.9%. This indicates strong capital allocation and a potential competitive advantage.
Harmony Biosciences Holdings, Inc. (HRMY) has a market capitalization of $2.0B. It is classified as a mid-cap stock.
Harmony Biosciences Holdings, Inc. (HRMY) does not currently pay a regular dividend.
Based on historical P/E analysis, Harmony Biosciences Holdings, Inc. (HRMY) appears fair. The current P/E of 13.0 is 17% below its historical median of 15.6. The estimated fair value CAGR (P/E method) is 44.9%.
Harmony Biosciences Holdings, Inc. (HRMY) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Harmony Biosciences Holdings, Inc. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 899M | 868M | 715M | 582M | 438M | 305M |
| Net Income | 146M | 159M | 145M | 129M | 181M | 35M |
| EPS | $2.53 | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 |
| Free Cash Flow | 0 | 348M | 219M | 219M | 144M | 98M |
| ROIC | 32.6% | 48.4% | 42.5% | 49.1% | 57.5% | 76.8% |
| Gross Margin | 76.5% | 77.2% | 78.1% | 79.2% | 63.7% | 51.2% |
| Debt/Equity | 0.17 | 0.19 | 0.28 | 0.42 | 0.48 | 1.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 190M | 208M | 191M | 192M | 120M | 88M |
| Operating Margin | 21.1% | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% |
| ROE | 16.0% | 20.8% | 25.8% | 29.6% | 61.6% | 24.4% |
| Shares Outstanding | 58M | 59M | 58M | 60M | 61M | 60M |
| Metric | ||||||||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | 160M | 305M | 438M | 582M | 715M | 868M | 899M |
| Gross Margin | N/A | 32.1% | 51.2% | 63.7% | 79.2% | 78.1% | 77.2% | 76.5% |
| R&D | 70M | 19M | 30M | 71M | 76M | 146M | 190M | 224M |
| SG&A | 36M | 40M | 64M | 84M | 95M | 110M | 153M | 154M |
| EBIT | -146M | 17M | 88M | 120M | 192M | 191M | 208M | 190M |
| Op. Margin | N/A | 10.6% | 28.7% | 27.4% | 33.0% | 26.7% | 24.0% | 21.1% |
| Net Income | -187M | -64M | 35M | 181M | 129M | 145M | 159M | 146M |
| Net Margin | N/A | -40.0% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% | 16.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -136.7% | 6.4% | 76.8% | 57.5% | 49.1% | 42.5% | 48.4% | 32.6% |
| ROE | 56.3% | 39.2% | 24.4% | 61.6% | 29.6% | 25.8% | 20.8% | 16.0% |
| ROA | -226.6% | -23.9% | 8.0% | 32.8% | 17.4% | 16.1% | 14.0% | 11.4% |
| Cash Flow | ||||||||
| Op. Cash Flow | -75M | -3.0M | 99M | 144M | 219M | 220M | 348M | 342M |
| Free Cash Flow | -76M | -3.0M | 98M | 144M | 219M | 219M | 348M | 0 |
| Owner Earnings | -89M | -18M | 64M | 95M | 163M | 153M | 279M | 275M |
| CapEx | 149K | 2K | 298K | 172K | 312K | 1.2M | 310K | 0 |
| Maint. CapEx | 3.2M | 10M | 19M | 23M | 24M | 24M | 24M | 24M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 3.2M | 10M | 19M | 23M | 24M | 24M | 24M | 24M |
| CapEx/OCF | N/A | N/A | 0.3% | 0.1% | 0.1% | 0.5% | 0.1% | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 167K | 0 | 0 | 100M | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.0% | N/A | N/A | 5.0% | N/A | N/A | 0.0% |
| Stock-Based Comp | 9.9M | 4.7M | 16M | 26M | 32M | 43M | 45M | 43M |
| Debt Repayment | 5.2M | 103M | 500K | 2.0M | 4.8M | 15M | 16M | 16M |
| Balance Sheet | ||||||||
| Net Debt | 73M | -34M | -39M | -129M | -157M | -286M | -606M | -482M |
| Cash & Equiv. | 24M | 229M | 234M | 244M | 312M | 453M | 753M | 641M |
| Long-Term Debt | 98M | 194M | 190M | 190M | 179M | 163M | 144M | 139M |
| Debt/Equity | -0.23 | 2.00 | 1.05 | 0.48 | 0.42 | 0.28 | 0.19 | 0.17 |
| Interest Coverage | -19.8 | 0.6 | 3.6 | 6.4 | 8.1 | 10.9 | 14.2 | 13.5 |
| Equity | -423M | 97M | 187M | 403M | 467M | 659M | 870M | 910M |
| Total Assets | 107M | 427M | 433M | 674M | 811M | 999M | 1.3B | 1.3B |
| Total Liabilities | 530M | 330M | 247M | 271M | 344M | 340M | 401M | 361M |
| Intangibles | 72M | 162M | 144M | 161M | 137M | 113M | 89M | 83M |
| Retained Earnings | -423M | -488M | -454M | -272M | -143M | 2.2M | 161M | 193M |
| Working Capital | 12M | 128M | 231M | 321M | 287M | 404M | 655M | 561M |
| Current Assets | 31M | 263M | 284M | 400M | 451M | 579M | 907M | 779M |
| Current Liabilities | 20M | 135M | 54M | 79M | 164M | 175M | 252M | 217M |
| Per Share Data | ||||||||
| EPS | -24.07 | -1.12 | 0.58 | 2.97 | 2.13 | 2.51 | 2.71 | 2.53 |
| Owner EPS | -11.39 | -0.31 | 1.07 | 1.55 | 2.70 | 2.64 | 4.77 | 4.75 |
| Book Value | -54.37 | 1.71 | 3.13 | 6.59 | 7.72 | 11.37 | 14.86 | 15.73 |
| Cash Flow/Share | -9.70 | -0.05 | 1.65 | 2.36 | 3.63 | 3.79 | 5.95 | 2.93 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 7.8M | 56.9M | 59.6M | 61.1M | 60.5M | 58.0M | 58.6M | 57.9M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | 74.1 | 18.2 | 15.6 | 13.6 | 14.1 | 14.0 |
| P/FCF | N/A | N/A | 26.1 | 22.9 | 9.2 | 9.1 | 6.4 | N/A |
| EV/EBIT | N/A | 118.1 | 28.8 | 26.4 | 9.7 | 9.0 | 7.9 | 8.2 |
| Price/Book | N/A | 21.0 | 13.7 | 8.2 | 4.3 | 3.0 | 2.6 | 2.2 |
| Price/Sales | N/A | 14.0 | 6.7 | 6.6 | 3.7 | 2.7 | 2.3 | 2.3 |
| FCF Yield | N/A | -0.1% | 3.8% | 4.4% | 10.9% | 11.0% | 15.6% | N/A |
| Market Cap | N/A | 2.0B | 2.6B | 3.3B | 2.0B | 2.0B | 2.2B | 2.0B |
| Avg. Price | N/A | 39.21 | 34.22 | 47.30 | 35.88 | 32.92 | 33.77 | 35.32 |
| Year-End Price | N/A | 35.86 | 42.97 | 54.05 | 33.33 | 34.20 | 38.13 | 35.32 |
Harmony Biosciences Holdings, Inc. passes 7 of 9 quality checks, indicating strong fundamentals.
Harmony Biosciences Holdings, Inc. trades at 13.0x trailing earnings, compared to its 15-year median P/E of 15.6x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 5.9x vs a median of 9.2x. The company's 5-year average ROIC is 54.9% with a gross margin of 69.8%. At current prices, the estimated annualized return to fair value is +64.7%.
Harmony Biosciences Holdings, Inc. (HRMY) reported annual revenue of $868 million in its most recent fiscal year, based on SEC EDGAR filings.
Harmony Biosciences Holdings, Inc. (HRMY) has a net profit margin of 18.3%. This is a healthy margin.
Harmony Biosciences Holdings, Inc. (HRMY) generated $348 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Harmony Biosciences Holdings, Inc. (HRMY) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
Harmony Biosciences Holdings, Inc. (HRMY) reported earnings per share (EPS) of $2.71 in its most recent fiscal year.
Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity (ROE) of 20.8%. This indicates the company generates strong returns for shareholders.
Harmony Biosciences Holdings, Inc. (HRMY) has a 5-year average gross margin of 69.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for Harmony Biosciences Holdings, Inc. (HRMY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Harmony Biosciences Holdings, Inc. (HRMY) has a book value per share of $14.86, based on its most recent annual SEC filing.